Francesca Chiara
Selected Reads
post by
Francesca Chiara, PhD, MPH, MRes

The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline

Frost I, Sati H, Garcia-Vello P, et al

14 December 2022

 

Access via The Lancet Microbe

 

 

Topics
Antimicrobial Stewardship

Publication summary

Prevention is a key step to reduce the spread of infectious diseases, and as a result of antimicrobial resistance. Vaccines play an important role in reducing infections caused by bacteria resistant to antibiotics and the use of antimicrobials. This paper looks at vaccine candidates targeting pathogens on the WHO Priority Pathogen List. Vaccines were classified in 4 groups depending on the stage of the candidates in the development pipeline.

 

Who this is for

  • Life science industry
  • Clinicians
  • Policy makers
  • Funding organizations

 

Key findings

  • The review identified 94 active preclinical vaccines candidates and 61 active development candidates.
  • Vaccines were organized in the following groups

Group A: existing vaccines, for example targeting S. enterica serotype Typhi, S. pneumoniae, H. influenzae type b, and M. tuberculosis.

Group B: vaccines in advance preclinical development, for example targeting extra-intestinal E. coli, S. serotype Paratyphi A, N. gonorrhoeae, and C. difficile.

Group C: vaccines in early phase of clinical development, for example targeting enterotoxigenic E. coli, K. pneumoniae, non-typhoidal Salmonella, Shigella spp, and Campylobacter spp

Group D: pathogens with no vaccines candidates or low feasibility, for example targeting P. aeruginosa, A. baumannii, S. aureus, H. pylori, E. faecium, and Enterobacter spp.

  • Many of the pathogens in Group D represent pathogens associated with hospital acquired infections whose affected patients/population at risk are difficult to target via traditional clinical trials. The authors suggest alternative measures to be explored as well as strengthening infection prevention and control practices.
  • There are three candidates for vaccine development for S. aureus but the feasibility of development is low due to intrinsic characteristics of the bacteria.
  • The mRNA vaccine technology has opened new prospects for vaccine development in future. There is currently one vaccine candidate for M. tuberculosis being developed with this technique.

Past posts

Information delay of significant bloodstream isolates and patient mortality: a retrospective analysis of 6,225 adult patients with bloodstream infection

This study evaluated the association between mortality and delays in reporting blood culture positivity and bacterial species identification in 6,225 patients with bacteremia treated at a Barcelona hospital from January 2013 to December 2019.

Natalie Vestin, MPH

The incidence of histoplasmosis and cryptococcal antigenemia among patients attending a large HIV clinic in Trinidad

This study evaluated the use of antigen assays to screen for Histoplasma capsulatum and Cryptococcus neoformans in 280 people living with HIV who had CD4+ counts of less than 350 cells per cubic millimeter (mm3) from November 2021 to June 2022 at an HIV clinic in Trinidad.

Natalie Vestin, MPH

New perspectives on primary prophylaxis of invasive fungal infection in children undergoing hematopoietic stem cell transplantation: a 10-year retrospective cohort study

This retrospective study evaluates the incidence of invasive fungal infections (IFIs) in 308 children who received an allogenic hematopoietic stem cell transplant in a French hospital that relies on environmental hygiene and air filtration, rather than systematic primary antifungal prophylaxis, from 2010 to 2020.

Natalie Vestin, MPH

Food and Drug Administration public workshop summary—development considerations of antifungal drugs to address unmet medical need

This article summaries discussions involving academia, the pharmaceutical industry, patient groups, and government agencies held during a 2020 US Food and Drug Administration (FDA) workshop to improve the regulatory and clinical trial infrastructure necessary to develop antifungals for invasive fungal infections.

Natalie Vestin, MPH

Approach to the diagnosis of invasive fungal infections of the respiratory tract in the immunocompromised host

This review examines the intersecting patient characteristics, clinical and imaging signs and pathways, and diagnostic tests available and in development to aid in rapid assessment of invasive fungal respiratory infections in immunocompromised people.

Natalie Vestin, MPH

Reservoirs of antimicrobial resistance in the context of One Health

This review highlights current insights into the emergence and spread of antimicrobial resistance (AMR) from a One Health perspective. A major challenge for One Health studies is attributing the directionality of transmission of antimicrobial resistance genes (ARGs) between different metagenomes.

 

 

Jamie Umber, DVM, MPH

Our underwriters